Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of amivantamab + lazertinib + bevacizumab after progression on third-generation EGFR TKI in EGFR-mutant NSCLC
NL-OMON56289Phase 2Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab, lazertinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Objective response rate at 12 weeks. Started Aug 2023; status: recruiting.
02
Drugs
amivantamablazertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56289.